Scroll to top

Scroll to top

News Releases

Home
Investors
News Releases

News Releases

Month Year

Month Year

Investor Alerts

March 25, 2019

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Vital Therapies Stockholders Vote “FOR” the Proposed Business Transaction With Immunic AG and All the Related Proposals
March 4, 2019

Vital Therapies Announces 2018 Financial Results
February 28, 2019

Immunic Therapeutics to Participate in Investor and Medical Conferences in March
February 26, 2019

Immunic Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of IMU-838, an Oral Therapy for Patients with Relapsing-Remitting Multiple Sclerosis
February 6, 2019

Immunic Therapeutics to Present at the BIO CEO & Investor Conference on February 11

Show per page